<DOC>
	<DOCNO>NCT02661789</DOCNO>
	<brief_summary>The project aim identifying neuropsychobiological signature pharmacological sex-steroid hormone manipulation healthy woman risk model depression . The study double-blind , randomize , placebo-controlled study . Investigators include 63 healthy female volunteer regular menstrual cycle 23 35 day . Participants randomize active Gonadotrophin-Releasing-Hormone agonist ( GnRHa ) ( goserelin 3.6 mg implant ) placebo ( saline injection ) intervention , initiate mid follicular phase ( i.e . cycle day 22.6 ±2.5 ) . Sixty woman complete follow-up entered analysis , except drop out domain . The following domain address baseline follow-up ( 16±3 day post intervention ) , ( correspond early ovarian suppression phase biphasic hormone response GnRHa ) : 1 ) serotonin transporter bind image 11CDASB Positron Emission Tomography ( PET ) , 2 ) functional Magnetic Resonance Imaging ( fMRI ) emotional processing , 3 ) fMRI reward processing , 3 ) rating state fMRI ( rsfMRI ) , 4 ) structural MRI , 5 ) Neuropsychology , 6 ) Psychophysiology , 7 ) Hypothalamus-Pituitary-Adrenal cortex ( HPA ) -axis dynamic , 8 ) Peripheral marker immunoactive cell response , 9 ) Epigenetic factor . Psychometrics term self report mental distress interview base rating monitor across intervention period monitor potential symptom mental distress psychopathology . Also ovarian hormone response , peripheral blood marker , side effect score collect across intervention period .</brief_summary>
	<brief_title>Neuropsychobiological Correlates Sex-steroid Hormone Manipulation Healthy Women : Risk Model Depression</brief_title>
	<detailed_description>Aims hypothesis : Gender matter normal brain function well neuropsychiatric disorder . E.g . vulnerability mood anxiety disorder considerably great woman . Among factor , possibly reflect gender difference central serotonergic function since dysfunction serotonergic neurotransmission critically involved pathophysiology mood anxiety disorder , schizophrenia , Alzheimer 's disease . In particular , woman go phase life sex hormone decline rapidly high level fluctuate , high frequency severe mood state change vulnerable psychiatric disorder , e.g . across pre postpartum menopausal transition . Interestingly , risk associate increased variability plasma level sex-hormone estradiol . Therefore , sex-hormone manipulation pharmacologically induced biphasic ovarian hormone response serve unique opportunity study sex-hormone fluctuation provoke mood state change increase vulnerability neuropsychiatric disorder . In project investigator aim investigate whether sex-hormone manipulation affect : 1 . Molecular image marker serotonergic neurotransmission vivo , 2 . Brain structure , architecture functional connectivity , 3 . Stress inflammatory response , 4 . Cognitive function , emotional processing , information filtering , importance pathophysiology neuropsychiatric disorder . Mentally healthy female volunteer assess baseline ( i.e cycle day 6.6 ±2.2 ) follow-up ( i.e 16.2 ±2.6 day post intervention ) early ovarian suppression phase af Gonadotrophin-Releasing-Hormone agonist response placebo-controlled , double-blinded design ( cohort size aim : N=30x2 ) . Research neurobiological correlate vulnerability relate sex-hormone change pivotal improve etiological understanding brain disorder gender difference incidence and/or nature . Such research may contribute ameliorate fertility treatment , improve treatment mood disorder schizophrenia , , ideally , shed light possible preventive strategy vulnerable phase woman 's life pre- post-partum menopausal transition period . Hypotheses : Investigators hypothesise sex-hormone manipulation associate following : 1 . Compromised serotonergic neurotransmission , 2 . Changes functional structural connectivity lower hippocampal brain volume and/or marker decrease neurogenesis , 3 . Increased stress reactivity inflammatory response , 4 . Changes neurocognitive function negative bias emotional processing information filtering . Investigators hypothesise change occur manner dependent magnitude estradiol drop baseline dependent symptom depress anxious mood . General study design : The study prospective , double-blinded , placebo-controlled , combine within-subject between-group design neuropsychobiological change response hormonal down-regulation . The investigation program perform baseline mid-follicular phase , day 5-8 menstrual cycle , down-regulated state , 14-19 day GnRHa intervention . Participants . Investigators aim include 60 healthy female volunteer , age range 18-40 year . Group 1 ( N=30 ) receive sex-hormone manipulation GnRHa , group 2 ( N=30 ) receive placebo ( saline injection ) . The inclusion stratify accord polymorphism serotonin transporter promoter region ( 5-HTLPR ) . The investigation program include functional brain image serotonin transporter [ 11C ] DASB PET ( 6 ) fMRI , structural brain imaging , blood measurement sex-hormone level , inflammatory epigenetic biomarkers , characterization cortisol awaken response , psychophysiological measure information processing , monitoring symptom mental distress psychopathology across intervention period . An initial screening program secure inclusion healthy control determine trait parameter genotype , IQ personality measure . The study register approved Danish Ethical Committee participant inclusion protocol identification number : H-2-2010-108 . All participant give write informed consent .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depression , Postpartum</mesh_term>
	<mesh_term>Nerve Degeneration</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Healthy woman Regular menstrual cycle ( 23 35 day cycle length ) No systemic intrauterine steroid hormone use Psychiatric disorder ( DSM IV Axis I WHO ICD10 diagnostic classification ) . Prior present neurological severe medical condition include substance abuse . No drug intake suspect influence result Conditions may increase risk participate study program include ovarian cyst Pregnancy last year Delivery last 2 year Presently wish obtain pregnancy Breast feeding Not fluent Danish severe visual hearing impairment Earlier present learn disability Claustrophobia ( due MRI scan ) Metal implant ( excludes MRI )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Mental health</keyword>
	<keyword>Brain Imaging</keyword>
	<keyword>Steroid hormone</keyword>
	<keyword>Serotonin</keyword>
	<keyword>PET</keyword>
	<keyword>MRI</keyword>
	<keyword>fMRI</keyword>
	<keyword>human</keyword>
	<keyword>gender</keyword>
	<keyword>risk model</keyword>
</DOC>